Category Archives: Guangdong

Policy Analysis & Guidance: Guangdong’s Medical Supply Price Disclosure and Procurement Expansion

Guangdong Province’s Drug Exchange Center has completed the price disclosure process for medical consumables submitted by enterprises before April 1, 2025. Products not receiving objections during the publicity period have been officially published and incorporated into the negotiated procurement framework. This move underscores Guangdong’s commitment to enhancing price transparency and efficiency in medical supply procurement.

Policy Breakdown

Price Confirmation: Enterprises confirmed pricing information through the provincial platform’s “New Negotiating Price Listing (Automatic Confirmation Project)” module.
Public Disclosure: Products without objections during the publicity period are now available for negotiated procurement at or below listed prices.
Follow-Up Actions: Products requiring information verification or with pending registration statuses will be listed after resolution.

Market Implications
The initiative is expected to streamline interactions between medical consumable suppliers and healthcare institutions, potentially accelerating market entry by 10–15%. Analysts at Guangdong Healthcare Market Research highlight improved price transparency as a key driver for reducing procurement costs.

Industry Impact
Medical consumable manufacturers are encouraged to align with Guangdong’s pricing and procurement frameworks to maintain market access. The policy emphasizes procedural integrity, reducing administrative burdens post-approval.

Looking Ahead
Stakeholders should monitor future pricing adjustments and supply list updates to stay informed of changes impacting market dynamics and procurement strategies.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1911060639980195840

Policy Analysis and Guidance: Guangdong’s Adjustment of Medical Supply Pricing

Guangdong Provincial Drug Exchange has announced an adjustment to the pricing of certain medical consumables on its third-party drug electronic trading platform. This initiative aims to optimize pricing rules, enhance price monitoring, and ensure fair and transparent transactions.

Key Policy Highlights

Pricing Adjustment
- Effective Date: The adjusted pricing for specific medical consumables will take effect from April 9, 2025.
- Product Details: Detailed information on the adjusted products is provided in the attachment for reference.
Preparation Requirements
- Transition Readiness: Relevant units need to prepare for online procurement and price transition of related products according to the actual situation.
Policy Background
- Basis: The adjustment is conducted in accordance with the “Notice on Optimizing and Perfecting the Listing Rules for Drugs and Consumables and Strengthening Price Monitoring” (粤医保函〔2023〕144号) and the “Announcement on the Implementation of Medical Consumable Listing Procurement on the Third-Party Drug Electronic Trading Platform of Guangdong Province”.

Policy Orientation and Industry Implications
The pricing adjustment policy reflects Guangdong’s strategic focus on:

Transparency: Enhancing transparency in medical consumable pricing through public disclosure.
Fair Pricing: Ensuring medical institutions can access products at fair and reasonable prices.
Market Efficiency: Promoting efficient distribution and procurement processes to support healthcare delivery.

Conclusion
Guangdong’s approach to adjusting medical consumable pricing sets a benchmark for regional medical product management, emphasizing transparency, fair pricing, and efficient distribution. Medical product enterprises should align with these guidelines to ensure smooth operations and contribute to healthcare efficiency.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907730520356163584

Policy Analysis and Guidance: Guangdong’s National Medical Product Review and Pricing Announcement

Guangdong Provincial Drug Exchange has announced the results of the national joint review and pricing for medical products in March 2025. This initiative aims to enhance transparency, ensure fair pricing, and support the efficient distribution of medical products.

Key Policy Highlights

Information Disclosure
- Purpose: To provide the public and medical institutions with accurate pricing information for newly listed medical products.
- Details: The announcement includes detailed pricing information for medical products that passed the review without objections during the display period.
Pricing Mechanism
- Negotiation: Products are included in the negotiated pricing procurement range, allowing medical institutions to purchase at prices not exceeding the listed prices.
- Efficiency: Streamlined processes ensure timely inclusion of products in the procurement range.
Post-Review Handling
- Information Verification: Products with pending information verification or incomplete registration certificates will be listed after verification is completed.
- Transparency: Ensuring all listed products meet regulatory standards and pricing requirements.

Policy Orientation and Industry Implications
The national joint review and pricing policy reflects Guangdong’s strategic focus on:

Transparency: Enhancing transparency in medical product pricing through public disclosure.
Fair Pricing: Ensuring medical institutions can access products at fair and reasonable prices.
Efficiency: Promoting efficient distribution and procurement processes to support healthcare delivery.

Conclusion
Guangdong’s approach to national medical product review and pricing sets a benchmark for regional medical product management, emphasizing transparency, fair pricing, and efficient distribution. Medical product enterprises should align with these guidelines to ensure smooth operations and contribute to healthcare efficiency.-China Health Reform Pulse

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1907745298520739840